Aqua Medical is a Santa Ana, CA-based medical device developer building a vapor-based, endoscopic Radio Frequency Vapor Ablation (RFVA) system for non-surgical outpatient treatment across the gastrointestinal tract. The company’s RFVA platform is being developed to treat Barrett’s esophagus, perform duodenal mucosal ablation to address insulin-resistant tissue in type 2 diabetes, and enable non-surgical treatment of precancerous pancreatic cysts with an ultrasound-guided needle catheter. The RFVA system received FDA 510(k) clearance and completed a first-in-man study for Barrett’s esophagus. Aqua Medical is led by founder and Chief Medical Officer Virender K. Sharma, MD, and President and CEO Lloyd Mencinger. The company intends to use the newly raised funds to advance clinical development and commercialization of its vapor-based ablation system across these high‑impact GI indications. Reported financials include completion of a $15.5M Series A financing, which incorporated an $8.2M Series A-3 equity tranche.

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2020